Hemolytic-Uremic Syndrome
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
1 programUsefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in PregnancyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
InmunovaINM004
AstraZenecaUsefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy
Clinical Trials (2)
Total enrollment: 295 patients across 2 trials
Efficacy of INM004 in Children With STEC-HUS
Start: Oct 2024Est. completion: Dec 2026220 patients
Phase 3Recruiting
NCT03580941AstraZenecaUsefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy
Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy
Start: Apr 2018Est. completion: Nov 202075 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 295 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.